The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes. There is conflicting data about the safety of these drugs regarding mortality and cardiovascular outcomes. The objective of the present study was to evaluate the safety of the sulfonylureas most frequently used and to use trial sequential analysis (TSA) to analyze whether the available sample was powered enough to support the results. METHODS AND FINDINGS: Electronic databases were reviewed from 1946 (Embase) or 1966 (MEDLINE) up to 31 December 2014. Randomized clinical trials (RCTs) of at least 52 wk in duration evaluating second- or third-generation sulfonylureas in the treatment of adults with type 2 diabetes and reporting outcomes of interest were included. Primary outcomes were all-cause and cardiovascular mortality. Additionally, myocardial infarction and stroke events were evaluated. Data were summarized with Peto odds ratios (ORs), and the reliability of the results was evaluated with TSA. Forty-seven RCTs with 37,650 patients and 890 deaths in total were included. Sulfonylureas were not associated with all-cause (OR 1.12 [95% CI 0.96 to 1.30]) or cardiovascular mortality (OR 1.12 [95% CI 0.87 to 1.42]). Sulfonylureas were also not associated with increased risk of myocardial infarction (OR 0.92 [95% CI 0.76 to 1.12]) or stroke (OR 1.16 [95% CI 0.81 to 1.66]). TSA could discard an absolute difference of 0.5% between the treatments, which was considered the minimal clinically significant difference. The major limitation of this review was the inclusion of studies not designed to evaluate safety outcomes. CONCLUSIONS: Sulfonylureas are not associated with increased risk for all-cause mortality, cardiovascular mortality, myocardial infarction, or stroke. Current evidence supports the safety of sulfonylureas; an absolute risk of 0.5% could be firmly discarded. REVIEW REGISTRATION: PROSPERO CRD42014004330.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 88 · cited 3×
“These contradictory results may be explained by the inclusion, or not, of first-generation sulfonylureas [19,20], observational studies [21,22], and short-term studies [18–21].”
BackgroundResultRetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 6×
“Therefore, the search strategy included the terms “type 2 diabetes” and “sulfonylureas” and used the recommended, highly sensitive Cochrane Collaboration strategy for RCT systematic reviews [26].”
BackgroundMethodInfluentialDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Even the recent published trials of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes and high cardiovascular risk did not show a reduction in cardiovascular events [11–13], but there was a concern regarding heart failure incidence in two of the trials [12,90].”
ResultGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734 · cited 1×
“In this setting, it is suggested that a sensitivity analysis with continuity correction be performed [37].”
BackgroundUndue reliance on I 2 in assessing heterogeneity may mislead
Rücker, G., Schwarzer, G., Carpenter, J. R., & Schumacher, M. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-79 · Cited by 1,287
(1970) · PubMed · Cited by 976
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938 · cited 2×
“summarize and aggregate dichotomous variables do not perform as expected in meta-analysis of rare events, and the risk of finding false positives is increased [26,35,36].”
BackgroundMethodNissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757 · cited 1×
“Even the recent published trials of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes and high cardiovascular risk did not show a reduction in cardiovascular events [11–13], but there was a concern regarding heart failure incidence in two of the trials [12,90].”
ResultCefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Bero, L. (1995) · JAMA · doi:10.1001/jama.1995.03530240045039 · Cited by 714
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667
Bhandari, M., Busse, J. W., Jackowski, D., Montori, V. M., Schünemann, H. J., Sprague, S., Mears, D., Schemitsch, E. H., Heels-Ansdell, D., & Devereaux, P. J. (2004) · Europe PMC (PubMed Central) · Cited by 551
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520 · cited 1×
“Because sulfonylureas are commonly used as a second agent in addition to metformin [1,33,34], we also assessed the effects of sulfonylureas when used as an add-on to metformin.”
BackgroundTzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444 · cited 3×
“Observational studies have reported conflicting results regarding sulfonylurea safety [8,14– 16], some of them disclosing an association of sulfonylurea use with increased risk of cardiovascular events [8,15].”
BackgroundResultBolland, M. J., Grey, A., Gamble, G. D., & Reid, I. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70212-2 · Cited by 422 · cited 1×
“Trial sequential analysis (TSA) is a tool that is increasingly being used [23] to assess whether optimal sample sizes—and benefit or harm boundaries—have been reached by an available sample of patients assuming a minimal clinically significant difference [24].”
MethodSchramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418 · cited 1×
“Observational studies have reported conflicting results regarding sulfonylurea safety [8,14– 16], some of them disclosing an association of sulfonylurea use with increased risk of cardiovascular events [8,15].”
ResultIncorporating considerations of resources use into grading recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Jaeschke, R., Helfand, M., Liberati, A., Vist, G. E., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39504.506319.80 · Cited by 412 · cited 1×
“The following items were considered to increase the quality of the evidence: a large magnitude of effect, the presence of a dose–response gradient, and if plausible biases worked to decrease the confidence of the finding [32].”
BackgroundRidderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366
Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60691-6 · Cited by 343
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events
Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H., & Clase, C. M. (2007) · Diabetes Care · doi:10.2337/dc06-1789 · Cited by 308
Roumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300
Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00994.x · Cited by 297
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
Diamond, G. A., Bax, L., & Kaul, S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00182 · Cited by 288 · cited 1×
“summarize and aggregate dichotomous variables do not perform as expected in meta-analysis of rare events, and the risk of finding false positives is increased [26,35,36].”
BackgroundNathan, D. M., Buse, J. B., Kahn, S. E., Krause-Steinrauf, H., Larkin, M. E., Staten, M., Wexler, D., Lachin, J. M., & the GRADE Study Research Group (2013) · Diabetes Care · doi:10.2337/dc13-0356 · Cited by 254
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
Monami, M., Genovese, S., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12116 · Cited by 251 · cited 4×
“These contradictory results may be explained by the inclusion, or not, of first-generation sulfonylureas [19,20], observational studies [21,22], and short-term studies [18–21].”
BackgroundResultInfluentialAhrén, B., Johnson, S. L., Stewart, M., Cirkel, D. T., Yang, F., Perry, C., & Feinglos, M. N. (2014) · Diabetes Care · doi:10.2337/dc14-0024 · Cited by 228
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Simpson, S. H., Lee, J., Choi, S., Vandermeer, B., Abdelmoneim, A. S., & Featherstone, T. R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70213-x · Cited by 223 · cited 1×
“A recent network meta-analysis—the preferable approach for comparing drugs that have not been directly compared—showed that second- and third-generation sulfonylureas had similar all-cause and cardiovascular mortality risks [89].”
ResultRao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Matthews, D. R., Dejager, S., Ahren, B., Fonseca, V., Ferrannini, E., Couturier, A., Foley, J. E., & Zinman, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01233.x · Cited by 199
Garber, A., Henry, R. R., Ratner, R., Hale, P., Chang, C. T., & Bode, B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01356.x · Cited by 196
Repaglinide versus glyburide: a one-year comparison trial
Marbury, T., Huang, W.-C., Strange, P., & Lebovitz, H. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00002-9 · Cited by 185
Roumie, C. L., Greevy, R. A., Grijalva, C. G., Hung, A. M., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2014) · JAMA · doi:10.1001/jama.2014.4312 · Cited by 173
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
Hirst, J. A., Farmer, A. J., Dyar, A., Lung, T. W. C., & Stevens, R. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2856-6 · Cited by 173 · cited 2×
“Because sulfonylureas are commonly used as a second agent in addition to metformin [1,33,34], we also assessed the effects of sulfonylureas when used as an add-on to metformin.”
Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics
Abbatecola, A. M., Rizzo, M. R., Barbieri, M., Grella, R., Arciello, A., Laieta, M. T., Acampora, R., Passariello, N., Cacciapuoti, F., & Paolisso, G. (2006) · Neurology · doi:10.1212/01.wnl.0000224760.22802.e8 · Cited by 168
Arjona Ferreira, J. C., Marre, M., Barzilai, N., Guo, H., Golm, G. T., Sisk, C. M., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Care · doi:10.2337/dc12-1365 · Cited by 159
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 154 · cited 4×
“These contradictory results may be explained by the inclusion, or not, of first-generation sulfonylureas [19,20], observational studies [21,22], and short-term studies [18–21].”
BackgroundResultInfluentialGross, J. L., Kramer, C. K., Leitão, C. B., Hawkins, N., Viana, L. V., Schaan, B. D., Pinto, L. C., Rodrigues, T. C., Azevedo, M. J., & for the Diabetes and Endocrinology Meta-analysis Group (DEMA)* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-10-201105170-00007 · Cited by 150 · cited 1×
“Because sulfonylureas are commonly used as a second agent in addition to metformin [1,33,34], we also assessed the effects of sulfonylureas when used as an add-on to metformin.”
BackgroundSelf-citationFilozof, C., & Gautier, J. ‐. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02938.x · Cited by 145
Rosenstock, J., Marx, N., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Bluhmki, E., Patel, S., Johansen, O.-E., & Woerle, H.-J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112475102 · Cited by 144
Ferreira, J. C. A., Corry, D. B., Mogensen, C. E., Sloan, L. A., Xu, L., Golm, G. T., Gonzalez, E. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.11.043 · Cited by 136
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012
Turner, L. W., Nartey, D., Stafford, R. S., Singh, S., & Alexander, G. C. (2014) · Diabetes Care · doi:10.2337/dc13-2097 · Cited by 136
Increased Prevalence of Upper Gastrointestinal Symptoms in Long-term Type 1 Diabetes Mellitus
Schvarcz, E., Palmér, M., Ingberg, C. M., Åman, J., & Berne, C. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199605)13:5<478::aid-dia104>3.0.co;2-5 · Cited by 129
Advantages of α-Glucosidase Inhibition as Monotherapy in Elderly Type 2 Diabetic Patients
Johnston, P. S., Lebovitz, H. E., Coniff, R. F., Simonson, D. C., Raskin, P., & Munera, C. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4824 · Cited by 129
Gerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116
Foley, J. E., & Sreenan, S. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1234042 · Cited by 105
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.881003 · Cited by 103
Prospective cohort studies: advantages and disadvantages
Sedgwick, P. (2013) · BMJ · doi:10.1136/bmj.f6726 · Cited by 100 · cited 1×
“However, observational studies have limitations because of selection and attrition bias, and from the results one can infer only association, and not causation [17].”
BackgroundGöke, B., Gallwitz, B., Eriksson, J. G., Hellqvist, Å., & Gause‐Nilsson, I. A. M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12119 · Cited by 90
Del Prato, S., Camisasca, R., Wilson, C., & Fleck, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12377 · Cited by 87
Rosenstock, J., Wilson, C., & Fleck, P. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12102 · Cited by 86
One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.
Campbell, I. W., Menzies, D. G., Chalmers, J., McBain, A. M., & Brown, I. R. F. (1994) · PubMed · Cited by 85
Kontopantelis, E., Springate, D. A., Reeves, D., Ashcroft, D. M., Rutter, M. K., Buchan, I. E., & Doran, T. (2014) · Diabetologia · doi:10.1007/s00125-014-3473-8 · Cited by 84 · cited 1×
“Instead, second- and third-generation sulfonylureas are widely used, and it is estimated that 20%–30% of patients with diabetes in developed countries are on sulfonylureas [9,10].”
BackgroundComparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study
Madsbad, S., Kilhovd, B., Lager, I., Mustajoki, P., Dejgaard, A., & for the Scandinavian Repaglinide Group (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00490.x · Cited by 79
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
Schernthaner, G., Durán‐Garcia, S., Hanefeld, M., Langslet, G., Niskanen, L., Östgren, C. J., Malvolti, E., & Hardy, E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12461 · Cited by 64 · cited 1×
“We identified one new study that would fulfill the inclusion criteria of this review [88].”
BackgroundTolman, K. G., Freston, J. W., Kupfer, S., & Pérez, A. (2009) · Drug Safety · doi:10.2165/11316510-000000000-00000 · Cited by 61
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
Klarenbach, S., Cameron, C., Singh, S., & Ur, E. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110178 · Cited by 60 · cited 1×
“Sulfonylureas are still used frequently in the treatment of patients with type 2 diabetes because they are effective in both improving glycemic control [1] and reducing the microvascular complications of diabetes [2]; in addition, they have the advantage of being inexpensive [3].”
BackgroundShould Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Hamann, A., Garcia-Puig, J., Paul, G., Donaldson, J., & Stewart, M. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-984441 · Cited by 49
Kaku, K., Rasmussen, M. F., Nishida, T., & Seino, Y. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00128.x · Cited by 47
Jain, R., Osei, K., Kupfer, S., Perez, A. T., Zhang, J., & Lannon, M. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.10.1388 · Cited by 47
Abrahamson, M. J. (2014) · Diabetes Care · doi:10.2337/dc14-1945 · Cited by 47
Nakamura, T., Sugaya, T., Kawagoe, Y., Ueda, Y., & Koide, H. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.633 · Cited by 45
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence
Leonard, C. E., Hennessy, S., Han, X., Siscovick, D. S., Flory, J., & Deo, R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.003 · Cited by 45
Markolf Hanefeld, E., Patwardhan, R., & Jones, N. P. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.12.003 · Cited by 42
Petrică, L., Petrica, M., Vlad, A., Jianu, D. C., Gluhovschi, G., Ianculescu, C., Dumitraşcu, V., Giju, S., Gluhovschi, C. A., Bob, F. R., et al. (2009) · Wiener klinische Wochenschrift · doi:10.1007/s00508-009-1279-3 · Cited by 39
Clauson, P., Karlander, S., Steen, L., & Efendic, S. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199605)13:5<471::aid-dia103>3.0.co;2-t · Cited by 34
Petrică, L., Vlad, A., Petrica, M., Jianu, D. C., Gluhovschi, G., Gădălean, F., Dumitraşcu, V., Ianculescu, C., Firescu, C., Giju, S., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.032 · Cited by 33
Giles, T. D., Elkayam, U., Bhattacharya, M., Perez, A., & Miller, A. B. (2010) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00154.x · Cited by 32
Quatraro, A., Consoli, G., Ceriello, A., & Giugliano, D. (1986) · PubMed · Cited by 32
Birkeland, K. I., Rishaug, U., Hanssen, K. F., & Vaaler, S. (1996) · Diabetologia · doi:10.1007/s001250050626 · Cited by 31
Ristic, S., Collober‐Maugeais, C., Cressier, F., Tang, P., & Pecher, E. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00632.x · Cited by 31
Alvarsson, M., Berntorp, K. E., Fernqvist‐Forbes, E., Lager, I., Steen, L., Örn, T., & Grill, V. (2010) · The Review of Diabetic Studies · doi:10.1900/rds.2010.7.225 · Cited by 30
Cardiovascular Effects of Diabetes Drugs: Emerging From the Dark Ages
Nissen, S. E. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00016 · Cited by 24
Vähätalo, M., Rönnemaa, T., & Viikari, J. S. A. (2007) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813430701507719 · Cited by 15
Perriello, G., Pampanelli, S., Brunetti, P., Pietro, C. D., & Mariz, S. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.044 · Cited by 14
The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70100-7 · Cited by 10
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
Онучин, С. Г., Елсукова, О. С., Solovev, O., & Onuchina, E. L. (2010) · PubMed · Cited by 9
Lundershausen, R., Orban, S., Pissarek, D., & Panzram, G. (1987) · PubMed · Cited by 6
Shi, B., Xing, Xiaoyan, X., Wang, N., Zhao, Wenhui, & Wen-ying, Y. (2014) · Cited by 2
We, Z. (2004) · Zhongguo xunzheng yixue zazhi · Cited by 1
Research works printed but not linked: 1
- Li MK, Liu Q, Yu ZZ, Cui SM, Shi P, et al (1999) [ Observation of the effect of combination of glipizide and insulin for type2 diabetic patients with secondary failure to oral sulfonylureas]. J Clin Int Med 15: 38.
Cited by
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“[174] Adverse cardiovascular outcomes with sulfonylureas in some observational studies have raised concerns, although findings from recent meta-analysis that included several RCTs reported that sulfonylureas when added to metformin were not associated with allcause mortality and CV mortality.[175] New generation sulfo…”
ResultGenetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
Metadata
- Authors
- Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-12
- Volume
- 13
- Issue
- 4
- Pages
- e1001992
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC4829174
- OpenAlex
- W2341376576
- Cited by
- 143
- References
- 102
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 18 · 2021: 11 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 24 · 2016: 4
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-06-24)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- sulfonylureas, type 2 diabetes, drug safety, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, trial sequential analysis, sample size adequacy
- MeSH terms
- Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Time Factors, Chi-Square Distribution, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.